Sopharma AD sells over three million treasury shares on Bulgarian Stock Exchange

Ognyan Ivanov Donev Chairman of the Board of Directors and Executive Director Sopharma AD
Ognyan Ivanov Donev Chairman of the Board of Directors and Executive Director - Sopharma AD
0Comments

Sopharma AD has announced the sale of 3,831,544 treasury shares on August 5, 2025. The transaction took place on the Bulgarian Stock Exchange and amounted to a total value of BGN 9,311,051.92. The average price per share was BGN 2.43.

The company stated that these shares represent 0.71% of its share capital. Following this sale, Sopharma AD holds a total of 21,438,370 treasury shares, which now account for 3.98% of its share capital.

According to the company: “Sopharma” AD (SFA: Bulgarian Stock Exchange, SPH: Warsaw Stock Exchange) notifies that on August 5, 2025 the Company sold 3 831 544 (three million eight hundred thirty-one thousand five hundred forty-four) repurchased own shares representing 0.71% of the share capital of the Company, at a total value of BGN 9 311 051.92 on the Bulgarian Stock Exchange, the average price per share was BGN 2.43.”

The disclosure is made in line with article 17 of Regulation (EU) No 596/2014 by the European Parliament and Council.



2 Comments
  • M tài khon binance says:
    Your comment is awaiting moderation. This is a preview; your comment will be visible after it has been approved.
    Your point of view caught my eye and was very interesting. Thanks. I have a question for you.
  • binance Sign Up says:
    Your comment is awaiting moderation. This is a preview; your comment will be visible after it has been approved.
    Your article helped me a lot, is there any more related content? Thanks! https://accounts.binance.info/kz/register-person?ref=K8NFKJBQ
  • Related

    Paul Hudson Chief Executive Officer Sanofi SA

    Acoziborole receives key EU panel backing as single-dose treatment for sleeping sickness

    Acoziborole Winthrop, a new oral treatment for sleeping sickness developed by the Drugs for Neglected Diseases initiative (DNDi) and Sanofi, has received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for…

    Martin Lundstedt President and CEO at Volvo Group North America LLC Volvo Group North America LLC

    Volvo announces updated share and vote count after series conversion

    The number of votes in AB Volvo has changed following the conversion of 2,000,619 Series A shares into an equal number of Series B shares.

    Paul Hudson Chief Executive Officer Sanofi SA

    Sanofi and Regeneron’s Dupixent recommended for EU approval in young children with chronic urticaria

    Sanofi and Regeneron have announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Dupixent (dupilumab) for children aged two to 11 years with…

    Trending

    The Weekly Newsletter

    Sign-up for the Weekly Newsletter from EU Business Daily.